We further analyzed molecular biomarkers reported in these immunotherapy data sets, including tumor mutation burden (TMB), individual gene mutation (PBRM1, BRCA2), T cell-inflamed gene expression profile (GEP), neoantigen load, cytolytic activity (CYT) and protein expression of checkpoints (CTLA-4, PD-L1, PD-L2)9,10,20–24. This evidence concerns the gene PBRM1 and neoplasm.